Iterum Therapeutics plc (ITRM)
NASDAQ: ITRM · Real-Time Price · USD
1.520
-0.020 (-1.30%)
At close: Jan 21, 2025, 4:00 PM
1.560
+0.040 (2.63%)
After-hours: Jan 21, 2025, 7:58 PM EST
Iterum Therapeutics Employees
Iterum Therapeutics had 14 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
14
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,182,429
Market Cap
41.82M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
ITRM News
- 2 months ago - Iterum Therapeutics Regains Full Nasdaq Compliance - GlobeNewsWire
- 2 months ago - Iterum Therapeutics plc (ITRM) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Iterum Therapeutics Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 3 months ago - Iterum Therapeutics plc (ITRM) U.S. FDA Approval of ORLYNVAH Call (Transcript) - Seeking Alpha
- 3 months ago - Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections - PRNewsWire
- 3 months ago - Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections - GlobeNewsWire
- 3 months ago - US FDA approves Iterum's treatment for urinary infection - Reuters
- 3 months ago - Iterum Therapeutics to Present Data at IDWeek 2024 - GlobeNewsWire